A novel selective CRF1 agonist (cortagine) was developed to dissect CRF receptor roles, confirming CRF1 drives anxiety while CRF2 mediates stress recovery — enabling more precise stress receptor pharmacology.
Key findingThe novel selective CRF1 agonist cortagine enabled clear dissection of CRF receptor roles: CRF1 activation drives anxiety/depression-like behavior whi
What the researchers found
The novel selective CRF1 agonist cortagine enabled clear dissection of CRF receptor roles: CRF1 activation drives anxiety/depression-like behavior while CRF2 activation promotes stress coping — precise tools for receptor-specific psychiatric drug development.
Why it matters
Relevant for neuropeptides, anxiety-mood.
How the study worked
review study on neuropeptides, anxiety-mood.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2005.
The bigger picture
Advances peptide/biomarker research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
The role of CRF receptors in anxiety and depression: implications of the novel CRF1 agonist cortagine.
Neuroscience and biobehavioral reviews, 29(8), 1323-33
Citation
Todorovic, Cedomir; Jahn, Olaf; Tezval, Hossein; Hippel, Cathrin; Spiess, Joachim. (2005). The role of CRF receptors in anxiety and depression: implications of the novel CRF1 agonist cortagine.. Neuroscience and biobehavioral reviews, 29(8), 1323-33.